Recruiting × INDUSTRY × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Clear all AUGMENT-101
Phase 1/2 Recruiting
447 enrolled 2 FDA
MOMENTUM
Phase 1/2 Recruiting
84 enrolled
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Phase 1 Recruiting
10 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
ALLight
Phase 1/2 Recruiting
83 enrolled
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Phase 1 Recruiting
30 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1 Recruiting
300 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
MK-1045-002
Phase 1/2 Recruiting
203 enrolled
INVISE
Phase 1 Recruiting
34 enrolled
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Phase 2 Recruiting
100 enrolled
cAMeLot-1
Phase 1/2 Recruiting
400 enrolled
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Phase 1 Recruiting
50 enrolled
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Phase 2 Recruiting
125 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
Phase 1 Recruiting
10 enrolled
LONGSAFE
Phase NA Recruiting
40 enrolled
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
263 enrolled 1 FDA
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 Recruiting
242 enrolled
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 Recruiting
44 enrolled
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Recruiting
40 enrolled
HOPE
Recruiting
10 enrolled
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Recruiting
100 enrolled
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
Phase 1 Recruiting
12 enrolled
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Phase NA Recruiting
50 enrolled
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Recruiting
200 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Recruiting
36 enrolled
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Phase 1/2 Recruiting
362 enrolled
CARLA
Phase 1 Recruiting
6 enrolled
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Phase 2 Recruiting
100 enrolled
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1 Recruiting
100 enrolled
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Phase 1/2 Recruiting
30 enrolled
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
Phase 1/2 Recruiting
36 enrolled